These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 37688739)

  • 1. Adjuvant and Neoadjuvant Treatments for Resectable Hepatocellular Carcinoma.
    Crook CJ; Li D
    Curr Oncol Rep; 2023 Oct; 25(10):1191-1201. PubMed ID: 37688739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic Neoadjuvant and Adjuvant Therapies in the Management of Hepatocellular Carcinoma-A Narrative Review.
    Chamseddine S; LaPelusa M; Kaseb AO
    Cancers (Basel); 2023 Jul; 15(13):. PubMed ID: 37444618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant versus Neoadjuvant Immunotherapy for Hepatocellular Carcinoma: Clinical and Immunologic Perspectives.
    Su YY; Li CC; Lin YJ; Hsu C
    Semin Liver Dis; 2021 Aug; 41(3):263-276. PubMed ID: 34130338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma.
    Samuel M; Chow PK; Chan Shih-Yen E; Machin D; Soo KC
    Cochrane Database Syst Rev; 2009 Jan; 2009(1):CD001199. PubMed ID: 19160192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials.
    Schwartz JD; Schwartz M; Mandeli J; Sung M
    Lancet Oncol; 2002 Oct; 3(10):593-603. PubMed ID: 12372721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical Trial.
    Rovers KP; Bakkers C; Nienhuijs SW; Burger JWA; Creemers GM; Thijs AMJ; Brandt-Kerkhof ARM; Madsen EVE; van Meerten E; Tuynman JB; Kusters M; Versteeg KS; Aalbers AGJ; Kok NFM; Buffart TE; Wiezer MJ; Boerma D; Los M; de Reuver PR; Bremers AJA; Verheul HMW; Kruijff S; de Groot DJA; Witkamp AJ; van Grevenstein WMU; Koopman M; Nederend J; Lahaye MJ; Kranenburg O; Fijneman RJA; van 't Erve I; Snaebjornsson P; Hemmer PHJ; Dijkgraaf MGW; Punt CJA; Tanis PJ; de Hingh IHJT;
    JAMA Surg; 2021 Aug; 156(8):710-720. PubMed ID: 34009291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Trials of Systemic Chemotherapy for Resectable Pancreatic Cancer: A Review.
    Mavros MN; Moris D; Karanicolas PJ; Katz MHG; O'Reilly EM; Pawlik TM
    JAMA Surg; 2021 Jul; 156(7):663-672. PubMed ID: 33787841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
    Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
    J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Overview of Clinical Trials in the Treatment of Resectable Hepatocellular Carcinoma.
    Nevarez NM; Chang GY; Yopp AC
    Surg Oncol Clin N Am; 2023 Jan; 32(1):101-117. PubMed ID: 36410911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival of Neoadjuvant and Adjuvant Therapy Compared With Surgery Alone for Resectable Esophageal Squamous Cell Carcinoma: A Systemic Review and Network Meta-Analysis.
    Ma Z; Yuan M; Bao Y; Wang Y; Men Y; Hui Z
    Front Oncol; 2021; 11():728185. PubMed ID: 34745950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival After Neoadjuvant and Adjuvant Treatments Compared to Surgery Alone for Resectable Esophageal Carcinoma: A Network Meta-analysis.
    Pasquali S; Yim G; Vohra RS; Mocellin S; Nyanhongo D; Marriott P; Geh JI; Griffiths EA
    Ann Surg; 2017 Mar; 265(3):481-491. PubMed ID: 27429017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant PD-1/PD-L1 Inhibitors for Resectable Head and Neck Cancer: A Systematic Review and Meta-analysis.
    Masarwy R; Kampel L; Horowitz G; Gutfeld O; Muhanna N
    JAMA Otolaryngol Head Neck Surg; 2021 Oct; 147(10):871-878. PubMed ID: 34473219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surgery and multimodal treatments in pancreatic cancer--a review on the basis of future multimodal treatment concepts.
    Link KH; Leder G; Formentini A; Fortnagel G; Kornmann M; Schatz M; Beger HG
    Gan To Kagaku Ryoho; 1999 Jan; 26(1):10-40. PubMed ID: 9987495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protocol of notable-HCC: a phase Ib study of neoadjuvant tislelizumab with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma.
    Zhang B; Yue J; Shi X; Cui K; Li L; Zhang C; Sun P; Zhong J; Li Z; Zhao L
    BMJ Open; 2022 Sep; 12(9):e060955. PubMed ID: 36115673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The current role of neoadjuvant/adjuvant/chemoprevention therapy in partial hepatectomy for hepatocellular carcinoma: a systematic review.
    Lau WY; Lai EC; Lau SH
    Hepatobiliary Pancreat Dis Int; 2009 Apr; 8(2):124-33. PubMed ID: 19357024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of Neoadjuvant Chemoradiation With and Without Systemic Chemotherapy in Resectable and Borderline Resectable Pancreatic Adenocarcinoma.
    Trinh KV; Fischer DA; Gardner TB; Smith KD
    Front Oncol; 2020; 10():1461. PubMed ID: 33042792
    [No Abstract]   [Full Text] [Related]  

  • 17. Neoadjuvant and adjuvant therapy for operable hepatocellular carcinoma.
    Chan ES; Chow PK; Tai B; Machin D; Soo K
    Cochrane Database Syst Rev; 2000; (2):CD001199. PubMed ID: 10796754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant and Adjuvant Systemic Therapies in Loco-Regional Treatments for Hepatocellular Carcinoma: Are We at the Dawn of a New Era?
    Nevola R; Delle Femine A; Rosato V; Kondili LA; Alfano M; Mastrocinque D; Imbriani S; Perillo P; Beccia D; Villani A; Ruocco R; Criscuolo L; La Montagna M; Russo A; Marrone A; Sasso FC; Marfella R; Rinaldi L; Esposito N; Barberis G; Claar E
    Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant Therapy for Resectable Pancreatic Cancer: An Evolving Paradigm Shift.
    Chawla A; Ferrone CR
    Front Oncol; 2019; 9():1085. PubMed ID: 31681614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.